Interleukin Protocols

Name: Interleukin Protocols
Brand: Humana Press Inc.
SKU: 9780896037380
Price: 2567 CZK
Availability: InStock

Autor: Luke A. J. O Neill, Andrew Bowie

Jazyk:

Vazba: Pevná

Vydavatel: Humana Press Inc.

Dostupnost: Skladem u dodavatele v malém množství

Odesíláme za 11-15 dnů

2 567 Kč

Interleukins are a family of proteins that regulate the maturation, diff- entiation, or activation o...

Informace o knize

Autor

Luke A. J. O Neill, Andrew Bowie

Jazyk

Angličtina

Vazba

Kniha - Pevná

Vydáno

2001

Stránek

443

EAN

9780896037380

ISBN

089603738X

Enbook ID

02716593

Vydavatel

Humana Press Inc.

Hmotnost

1870

Rozměry

155 x 235 x 29

Kompletní popis

Interleukins are a family of proteins that regulate the maturation, diff- entiation, or activation of cells involved in immunity and inflammation, and belong to a broader family termed cytokines. Collectively these proteins are the key orchestrators of host defense and the response to tissue injury. There are currently 23 different interleukins (numbered from IL-1 to IL-23), although the full extent of the interleukin family will only become clear upon analysis of the human genome sequence. Most important, interleukins are central to the pathogenesis of a wide range of diseases that involve an immune com- nent, including such conditions as rheumatoid arthritis, multiple sclerosis, ulcerative colitis, psoriasis, and asthma. Interleukins have also been imp- cated in other conditions, including cancer, migraine, myocardial infarction, and depression. In essence, when cells are activated by interleukins, a program of gene expression is initiated in the target cell that alters the cell s phenotype, leading to enhanced immune reactivity, inflammation, and/or proliferation. Interleukins are therefore at the core of the cellular basis for many diseases. They are the subject of intense investigation by biomedical researchers and the targeting or use of interleukins in the clinic is proceeding apace. Approaches such as t- geting IL-4 in asthma or IL-1 in joint disease are being pursued, and it is likely that in the next 5 10 years a number of new therapies based on either inhib- ing or administering interleukins will be available.

Mohlo by vás zajímat

Zákaznicí kteří koupili tuto knihu koupili také

Nejčastěji hledané

Categories

Authors

Publishers

Produkty

Produkty

Nejčastěji hledané

Categories

Authors

Publishers

Produkty

Produkty

Interleukin Protocols

Informace o knize

Kompletní popis

Mohlo by vás zajímat

Zákaznicí kteří koupili tuto knihu koupili také